Tagged with china

China Global medical aesthetics market leader Allergan is investing heavily in the Chinese city of Chengdu and has launched a number of initiatives there, including a global consumer experience centre, an R&D-focused innovation centre, and a brand awareness drive for both consumers and potential future employees.   The Chinese medical aesthetics…

China Dr Li Shuai of pain- and CNS-focused Chinese biotech SIMR outlines the history of the company, the unmet medical needs it is seeking to address, its partnership strategy, and the complexities of attracting and retaining talent in the highly competitive Chinese market.   In 2014, my first angel investor actually…

China Zhenkun Ma, founder and CEO of TenNor Therapeutics, shares his cross-sectorial experiences in Big Pharma, biotech and non-profit organization that led to the establishment of TenNor Therapeutics; their mission to develop highly differentiated therapies for infectious diseases with clear unmet medical needs, such as biofilm-associated medical device infections, H. pylori…

Taiwan With the USA and China locked in a trade war, China’s near neighbour Taiwan – with its strong scientific and technology base, political security and economic reliability – may stand to benefit from the situation, attracting more investment from the US and more closely collaborating with US firms and research…

China The US FDA has granted orphan drug designation to Shanghai-headquartered biotech CARsgen Therapeutics’ CAR-T cell therapy CT053 for multiple myeloma after positive results were observed in the phase I trial efficacy evaluation.   19 of 24 patients with relapsed and refractory multiple myeloma showed complete response Zonghai Li, CARSgen Therapeutics…

China Competition is heating up among Asian stock exchanges hoping to lure the hottest prospects in Chinese biotech to list there. The newest competitor, Shanghai’s STAR Board, has already attracted over 100 companies, some of which have reconsidered listing on the Hong Kong Exchange, wary of the HKEX’s lukewarm performance.  …

China Earlier this year, PharmaBoardroom highlighted five of the most innovative and important biotech companies making waves in the world’s second-largest pharmaceutical market, China. Here, we pick out five more firms looking to crack both the Chinese and international markets.   EpimAB Biotherapeutics Founded in 2015, EpimAb Biotherapeutics is a privately owned…

China Dr Kai Lamottke, co-founder and MD of Bicoll GmbH, Munich, and since 2001, GM and board member of Bicoll Biotechnology (Shanghai) Co. Ltd discusses Bicoll’s presence in both the Chinese and European markets, its unique Bicoll Plant ProfilesTM (fine fractions derived from plant extracts fractionated by Bicoll’s innovative isolation system…

China Jim Xu, GM of Medidata China, shares the importance of the China market to Medidata Solutions, the global leader in cloud services and solutions to the life sciences industry; his three priorities to foster stronger customer relationships, build talent, and deliver our offerings locally to the China market; as well…

China Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which is Old Norse for ‘to cure, to heal’. He also outlines Laekna’s focus on disease biology, specifically the areas of…

China Tony Acciarito, President of Thermo Fisher Scientific China, explains how he is delivering the company’s mission of ‘enabling our customers to make the world healthier, cleaner and safer’ in China, the importance of entrepreneurial thinking and agility to the China market, the significant investments they have made here, and his…

China Zheru Zhang and Jielun Zhu of I-Mab Biopharma, shares their vision for the ambitious biotech company looking to develop their dual-pronged strategy of in-licensing ‘fast-to-market’ assets for their China portfolio while accelerating proof-of-concept of their internally developed candidates; what it means to operate at ‘I-Mab speed’, not just ‘China Speed’;…